The best drug discovery platform

Projektinformationen

Ultimate

ID Finanzhilfevereinbarung: 728924

DOI

10.3030/728924

Projekt abgeschlossen

EK-Unterschriftsdatum 23 Mai 2016

Startdatum 1 Juni 2016

Enddatum 30 November 2016

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

MCULE.COM KFT
Hungary

Periodic Reporting for period 1 - Ultimate (The best drug discovery platform)

Berichtszeitraum: 2016-06-01 bis 2016-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Development of one new drug can take about 15 years and cost up to 2 billion USD. The first step of the process is called drug discovery. At least 10,000 compounds are tested in the discovery phase and only 5 of them on average reach clinical trials. The loss due to research on failed compounds is about 27 million USD for one new drug. The success of the process depends on the selection of good molecules as starting points. Mcule aims to provide the best web-based drug discovery platform for pharmaceutical researchers (pharma companies, contract research organisations and academics). We aim to create an easily searchable chemical database of 500 million purchasable compounds, the Ultimate database, with standard parameters: minimum 80% synthetic success rate, maximum 6 weeks of delivery time, fixed prices. The Ultimate database would include virtual (not yet synthesized, but predicted to be synthesizable) compounds.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

In Mcule we provide a web-based drug discovery platform, which enables scientists to identify, optimize and order hits and leads faster. In the Ultimate project, we shall extend the existing chemical space with molecules that can be synthetized in an economically reliable way, and develop the algorithm for a searching tool that enables browsing on such big database. During the phase 1 project we made detailed market assessment and refined the need of our users. We assessed the project risks and IP protection possibilities as well as updated our business plan. We established partnership with world leading institutions and companies. We decided to continue the project and apply for SME Instrument Phase 2 grant.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The key novelty of our innovation is that we make searchable the chemical space which is not synthesized but can be produced with reasonable effort. The ULTIMATE database is partly created by an “artificial chemist”, an intelligent in silico chemistry brain for practically instantaneous decisions on synthetic reaction evaluation producing synthetically feasible, new lead-like scaffold derivatives and building blocks. Besides the size of our database, we provide an easy-to-use chemical web-shop and multiple delivery options.
The Ultimate database will expectedly make pharmaceutical research more effective (higher hit-to-lead and lead-to-clinic ratios) and thus contribute to environmental friendly (less waste) and more economical (less cost) drug discovery.

ultimate-figure.jpg